ELLA-CS
ELLA-CS, s.r.o. is a Czech medical device manufacturer that designs and sells proprietary biodegradable and conventional esophageal and airway stents to hospitals and healthcare institutions worldwide, complemented by OEM and contract manufacturing services.
- Company typePrivate
- Founded1995
- HeadquartersHradec Kralove, Czechia
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What ELLA-CS does
ELLA-CS, s.r.o. is a Czech medical device manufacturer specializing in stents for the digestive tract (gastroenterology) and respiratory tract (pneumology). Headquartered in Hradec Králové, Czech Republic, the company designs, manufactures, and distributes esophageal and airway stents to hospitals and healthcare institutions worldwide. Its commercial product portfolio centers on the BD STENT, a biodegradable esophageal stent described by the company as worldwide unique, the DANIS STENT for critical esophageal conditions, and the HV STENT Plus for digestive and respiratory obstructions. The company is also developing a Hybrid Stent combining biodegradable and metallic components, with a patent application filed. Underlying technology is rooted in materials science and mechanical stent design — notably proprietary biodegradable polymer stent architecture that eliminates the need for removal procedures — rather than software or AI.
The company's business model is B2B medical device manufacturing, executed via direct institutional sales to hospitals and healthcare providers globally. Revenue is generated through two streams: (1) hardware sales of its proprietary stent portfolio and (2) OEM and contract manufacturing services for third-party medical device partners. Go-to-market is enterprise field sales, supported by participation in international medical conferences and trade fairs (ESGE Days, MedtecLIVE, WHX) and professional website content directed at healthcare professionals. Pricing is not publicly disclosed and is handled through direct quotation and procurement processes typical of medical device institutional sales. The primary customer segment is acute care hospitals, university medical centers, and specialized healthcare facilities performing gastroenterology and pneumology procedures; a secondary patient-facing segment is targeted through patient education resources.
ELLA-CS operates as a privately held limited liability company (s.r.o.) with no disclosed parent company, no external investment or venture backing, and no subsidiaries. The firm has accumulated 30 years of manufacturing experience, holds multiple Czech and European quality and innovation awards (including Czech Innovation Award 2012, European Business Awards National Winner 2014/2018/2019, Safe Enterprise 2025, and Ambassador of Quality Czech Republic 2025), and is pursuing EU MDR 2017/745 quality management system certification. Its R&D, clinical trials, commercialization preparation, and export market expansion activities have received co-sponsorship from the European Union and Czech Republic, supporting a long-term, government-aligned innovation and internationalization strategy.
ELLA-CS firmographics
Firmographics- Name
- ELLA-CS
- Legal name
- ELLA-CS, s.r.o.
- Website
- https://ellacs.eu
- Company type
- Private
- Founded year
- 1995
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- ELLA-CS, s.r.o. is a Czech medical device manufacturer that designs and sells proprietary biodegradable and conventional esophageal and airway stents to hospitals and healthcare institutions worldwide, complemented by OEM and contract manufacturing services.
- Ownership category
- akta.pro rank
ELLA-CS industry classification
Industry- Product category
- Medical Devices (Gastroenterology and Pneumology Stents)
- NAICS
- Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Coronary Stents & Drug-Eluting Technologies (HLAHAFAA)
- akta.pro secondary industry
- Peripheral Vascular Intervention (PAD Stents, Balloons, Atherectomy) (HLAHAFAE)
Keywords
Where ELLA-CS is headquartered
LocationHeadquarters
- HQ city
- Hradec Kralove
- HQ country
- Czechia
- HQ region
- Europe
Offices1 record
Markets served
ELLA-CS business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales
Revenue model
- Medical Device Sales: ELLA-CS generates revenue through the manufacture and sale of medical stents and related medical devices for gastroenterology and pneumology applications to healthcare institutions worldwide.
- OEM and Contract Manufacturing: The company offers cooperation in projects through OEM (Original Equipment Manufacturing) and contract manufacturing services for medical devices.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
ELLA-CS product offering
Product offeringCore offering
ELLA-CS manufactures and sells specialized medical stents for gastroenterology and pneumology applications. Its portfolio includes the BD STENT (a worldwide unique biodegradable esophageal stent that dissolves in the body), the DANIS STENT (a life-saving esophageal stent for critical conditions), and the HV STENT Plus (esophageal/airway stent). The company also offers OEM and contract manufacturing services for medical devices.
Product overview
ELLA-CS is a Czech medical device manufacturer specializing in gastroenterology and pneumology stents. The company offers a portfolio of esophageal and airway stents, including the BD STENT (biodegradable esophageal stent), DANIS STENT (life-saving esophageal stent), and HV STENT Plus. The company also develops a Hybrid Stent combining biodegradable and metallic technologies. ELLA-CS supplies its unique stents worldwide, with products designed for the digestive tract and airway applications. The company operates in gastroenterology and pneumology categories.
Differentiator
Problem solved
Functional benefit
Brands
- BD STENT: Worldwide unique biodegradable esophageal stent
- DANIS STENT
- HV Stent Plus
Products and services
- BD STENT A worldwide unique biodegradable esophageal stent designed for treatment of esophageal strictures and obstructions; dissolves in the body over time, eliminating the need for removal procedures. Targeted at gastroenterology specialists and hospitals.
- DANIS STENT A life-saving esophageal stent designed for urgent and critical esophageal conditions, providing structural support and palliation for patients with esophageal obstructions. Used by hospitals and gastroenterology specialists.
- HV STENT Plus An esophageal/airway stent designed to restore hope for patients with limitations due to digestive or respiratory tract obstructions, helping patients return to normal life. Targeted at hospitals and specialists treating airway and digestive tract obstructions.
- OEM and Contract Manufacturing Services Cooperation in projects in the form of OEM (Original Equipment Manufacturing) and contract manufacturing for medical devices. Targeted at medical device companies seeking manufacturing partners.
Quantifiable outcome
- 303 days hospitalization reduced to discharge after biodegradable stent implantation
Companies that use ELLA-CS
Customer profileNamed customers1 record
Segments2 records
Ideal customer profiles2 records
ELLA-CS technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
ELLA-CS partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- European Union and Czech RepubliccoreEU and Czech Republic co-sponsorship of multiple research and development projects including biodegradable stent development, commercialization preparation, clinical trials, and quality management system certification (MDR compliance). Multiple projects supported including marketing initiatives, 3D animation development, and export market expansion.
Scale indicators3 records
Recent moves6 records
Expansion highlights5 records
ELLA-CS competitors and assessment
Company assessmentDirect peers
- Taewoong Medical: Taewoong Medical is a Korea-based specialist in GI and airway stents (Niti-S, etc.) and is the most direct global competitor to ELLA-CS in the esophageal and biliary stent space, with comparable indications and physician customers.
- Merit Medical Systems: Merit Medical manufactures non-vascular stent systems (including esophageal and airway platforms) and competes head-to-head with ELLA-CS in gastroenterology and pneumology stents sold to hospitals worldwide.
- Cook Medical: Cook Medical is a leading direct competitor in GI and airway stents, offering a broad portfolio of esophageal, biliary, and bronchial stents — overlapping directly with ELLA-CS's core product categories of gastroenterology and pneumology stent systems.
- Leufen Medical: Leufen Medical is a European specialist in airway and esophageal stents with comparable positioning to ELLA-CS, serving pulmonologists and gastroenterologists with overlapping indications.
- Hood Laboratories: Hood Laboratories produces silicone airway stents and related products for pneumology, overlapping with ELLA-CS's airway stent offerings and competing for the same ENT and pulmonology customers.
Broad incumbents
- Medtronic: Medtronic is a broad incumbent in medical devices and competes with ELLA-CS in airway and esophageal stent categories (e.g., EndoFLX heritage airway products, Wallstent legacy esophageal portfolio), representing a much larger competitor with deep sales infrastructure.
- Olympus Corporation: Olympus is a leading player in GI endoscopy and supplies complementary devices including esophageal stents through partnered portfolios, competing with ELLA-CS in the same gastroenterology procedure workflows and hospital channels.
- Boston Scientific: Boston Scientific is a global broad incumbent in endoscopy and interventional medicine, with a large GI stent franchise (WallFlex, Ultraflex) directly competing with ELLA-CS in esophageal stenting, while also serving as a benchmark on commercialization scale and regulatory footprint.
Emerging players
- M.I. Tech: M.I. Tech (Korea) is an emerging player in GI and airway stents (Hanarostent family), competing with ELLA-CS in similar endoscopic indications across European and Asian export markets.
- Micro-Tech (Nanjing): Micro-Tech is a Chinese manufacturer of GI endoscopic accessories including stents, providing a low-cost emerging alternative to ELLA-CS in international tenders and emerging markets.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
ELLA-CS social profiles
Digital presenceELLA-CS compliance and trust
Trust signalCompliance18 records
ELLA-CS financial estimates
Financial estimateRevenue estimate
Valuation estimate
ELLA-CS leadership team
Management profileNumber of profiles
ELLA-CS funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ELLA-CS M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ELLA-CS
What does ELLA-CS do?
ELLA-CS manufactures and sells specialized medical stents for gastroenterology and pneumology applications. Its portfolio includes the BD STENT (a worldwide unique biodegradable esophageal stent that dissolves in the body), the DANIS STENT (a life-saving esophageal stent for critical conditions), and the HV STENT Plus (esophageal/airway stent). The company also offers OEM and contract manufacturing services for medical devices.
Is ELLA-CS a public or private company?
ELLA-CS is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was ELLA-CS founded?
ELLA-CS was founded in 1995. It employs 11 to 50 people.
Where is ELLA-CS based?
ELLA-CS is headquartered in Hradec Kralove, Czechia, in the Europe region.
How does ELLA-CS make money?
Two revenue lines are on record. Medical Device Sales are the primary driver. The others are OEM and Contract Manufacturing.
Who are ELLA-CS's main competitors?
Direct peers on record are Taewoong Medical, Merit Medical Systems, Cook Medical, Leufen Medical and Hood Laboratories. Broad incumbents are Medtronic, Olympus Corporation and Boston Scientific. Emerging players are M.I. Tech and Micro-Tech (Nanjing).
Does ELLA-CS have an API?
No public API is recorded for ELLA-CS.
What industry is ELLA-CS in?
ELLA-CS's product category is Medical Devices (Gastroenterology and Pneumology Stents). Its primary akta.pro industry code is HLAHAFAA, Coronary Stents & Drug-Eluting Technologies, with a secondary code of HLAHAFAE, Peripheral Vascular Intervention (PAD Stents, Balloons, Atherectomy). Its NAICS code is 339113 and its SIC code is 3841.